Encephalopathy: Cause, Pathogenesis, and Treatment

Area of Science:

• Neurocritical Care
• Neuropharmacology
• Natural Product Chemistry

Background:

• Encephalopathy encompasses diffuse brain dysfunction from systemic issues like infections, metabolic disorders, and organ failure.
• Key subtypes include sepsis-associated, hepatic, hypoxic-ischemic, diabetic, uremic, and toxic encephalopathies.
• Current neurocritical care lacks effective neuroprotective interventions, necessitating novel therapeutic strategies.

Purpose of the Study:

• To systematically review the etiopathogenesis of major encephalopathies.
• To emphasize the molecular mechanisms and cellular targets of small molecule drugs, especially natural products.
• To address limitations in mechanistic insights, target identification, and clinical translation for neuroprotection.

Main Methods:

• Systematic synthesis of contemporary evidence on encephalopathy etiopathogenesis.
• Focus on molecular mechanisms and cellular targets of small molecule drugs, particularly natural products.
• Critical assessment of current research limitations and challenges in clinical translation.

Main Results:

• Natural small molecules show promise for multitarget and network-level modulation of pathogenic processes in encephalopathy.
• Significant gaps exist in understanding the precise mechanisms and target networks of these compounds.
• Clinical translation of neuroprotective strategies derived from small molecules is currently insufficient.

Conclusions:

• Natural small molecules offer a promising avenue for developing novel neuroprotective strategies against encephalopathy.
• Further research is crucial to elucidate detailed mechanistic insights and define target networks.
• Establishing a robust framework is essential for guiding the clinical translation of these potential therapies.